DWP
RVNC

Daymark Wealth Partners’s Revance Therapeutics, Inc. RVNC Stock Holding History

Daymark Wealth Partners’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,000
Closed -$77.8K – 530
2024
Q3 		$77.8K Sell
15,000
-61,000
-80% -$303K ﹤0.01% 508
2024
Q2 		$195K Buy
76,000
+30,000
+65% +$102K 0.01% 486
2024
Q1 		$226K Buy
46,000
+17,000
+59% +$101K 0.01% 395
2023
Q4 		$255K Buy
29,000
+5,000
+21% +$41K 0.02% 344
2023
Q3 		$275K Buy
24,000
+10,000
+71% +$192K 0.02% 319
2023
Q2 		$354K Buy
+14,000
New +$436K 0.03% 279

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Daymark Wealth Partners's RVNC Position: Q4 2024 in Review

Daymark Wealth Partners sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 15,000 shares — an estimated $77.8K sold.

Daymark Wealth Partners first reported a position in RVNC in Q2 2023 and held it in 6 quarters. The position peaked at $354K in Q2 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Daymark Wealth Partners reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Daymark Wealth Partners sold 15,000 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $77.8K.
  • Daymark Wealth Partners first reported a position in Revance Therapeutics, Inc. in Q2 2023 and held it in 6 quarters.
  • Daymark Wealth Partners's Revance Therapeutics, Inc. position peaked at $354K in Q2 2023.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Daymark Wealth Partners's 13F filing for Q4 2024, filed 17 Jan 2025.